Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation

Liver Transplantation

Volumn 17, Issue SUPPL. 2, 2011, Pages

  Kneteman, Norman ^a   Livraghi, Tito ^b   Madoff, David ^c   De Santibañez, Eduardo ^d   Kew, Michael ^e  

^a UNIVERSITY OF ALBERTA   (Canada)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CYCLINE; DECARBOXYPROTHROMBIN; FERRITIN; FLUORODEOXYGLUCOSE F 18; MESSENGER RNA; MYC PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER;

CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; FERRITIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; IMAGING SYSTEM; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

CARCINOMA, HEPATOCELLULAR; DECISION SUPPORT TECHNIQUES; DIAGNOSTIC IMAGING; EVIDENCE-BASED MEDICINE; HEALTH STATUS INDICATORS; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WAITING LISTS;

EID: 80053284282     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22334     Document Type: Note

References (54)

1. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010; 16: 262-278.
2. Freeman RB, Mithoefer A, Ruthazer R, Nguyen K, Schore A, Harper A, Edwards E,. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl 2006; 12: 1504-1511. (Pubitemid 44594281)
3. Shah SA, Tan JC, McGilvray ID, Cattral MS, Cleary SP, Levy GA, et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006; 81: 1633-1639. (Pubitemid 43948294)
4. Taouli B, Krinsky GA,. Diagnostic imaging of hepatocellular carcinoma in patients with cirrhosis before liver transplantation. Liver Transpl 2006; 12 (suppl 2): S1-S7. (Pubitemid 44742515)
5. Willatt JM, Hussain HK, Adusumilli S, Marrero JA,. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247: 311-330.
6. Lu CH, Chen CL, Cheng YF, Huang TL, Tsang LL, Ou HY, Chen TY,. Correlation between imaging and pathologic findings in explanted livers of hepatocellular carcinoma cases. Transplant Proc 2010; 42: 830-833.
7. Bruix J, Sherman M,; for Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236. (Pubitemid 43112690)
8. Lee DH, Kim SH, Lee JM, Park HS, Lee JY, Yi NJ, et al. Diagnostic performance of multidetector row computed tomography, superparamagnetic iron oxide-enhanced magnetic resonance imaging, and dual-contrast magnetic resonance imaging in predicting the appropriateness of a transplant recipient based on Milan criteria: correlation with histopathological findings. Invest Radiol 2009; 44: 311-321.
9. Bennett GL, Krinsky GA, Abitbol RJ, Kim SY, Theise ND, Teperman LW,. Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. AJR Am J Roentgenol 2002; 179: 75-80. (Pubitemid 34694814)
10. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 2008; 98: 1166-1175. (Pubitemid 351481685)
11. Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006; 12: 1655-1660. (Pubitemid 44742545)
12. Yamamoto Y, Nishiyama Y, Kameyama R, Okano K, Kashiwagi H, Deguchi A, et al. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med 2008; 49: 1245-1248.
13. Kornberg A, Küpper B, Thrum K, Katenkamp K, Steenbeck J, Sappler A, et al. Increased 18F-FDG uptake of hepatocellular carcinoma on positron emission tomography independently predicts tumor recurrence in liver transplant patients. Transplant Proc 2009; 41: 2561-2563.
14. Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, Chung JK, et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009; 50: 682-687.
15. Kim YK, Lee KW, Cho SY, Han SS, Kim SH, Kim SK, Park SJ,. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transpl 2010; 16: 767-772.
16. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699. (Pubitemid 26079803)
17. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP,. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007; 7: 2587-2596. (Pubitemid 47561609)
18. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al.; for Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
19. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM,. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832-838.
20. Xu X, Ke QH, Shao ZX, Wu J, Chen J, Zhou L, Zheng SS,. The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. Dig Dis Sci 2009; 54: 385-388.
21. Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, et al. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery 2007; 141: 598-609. (Pubitemid 46616932)
22. Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10: 911-918. (Pubitemid 38979263)
23. Figueras J, Ibañez L, Ramos E, Jaurrieta E, Ortiz-de-Urbina J, Pardo F, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl 2001; 7: 877-883. (Pubitemid 33040462)
24. Ho MC, Wu YM, Hu RH, Ko WJ, Yang PM, Lai MY, et al. Liver transplantation for patients with hepatocellular carcinoma. Transplant Proc 2004; 36: 2291-2292.
25. Guzman G, Alagiozian-Angelova V, Layden-Almer JE, Layden TJ, Testa G, Benedetti E, et al. p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Mod Pathol 2005; 18: 1498-1503. (Pubitemid 41509405)
26. John AR, Khan S, Mirza DF, Mayer AD, Buckels JS, Bramhall SR,. Multivariate and univariate analysis of prognostic factors following resection in HCC: the Birmingham experience. Dig Surg 2006; 23: 103-109. (Pubitemid 44174848)
27. Del Gaudio M, Grazi GL, Principe A, Ravaioli M, Ercolani G, Cescon M, et al. Influence of prognostic factors on the outcome of liver transplantation for hepatocellular carcinoma on cirrhosis: a univariate and multivariate analysis. Hepatogastroenterology 2004; 51: 510-514. (Pubitemid 38445306)
28. Lohmann R, Bechstein WO, Langrehr JM, Knoop M, Lobeck H, Keck H, et al. Analysis of risk factors for recurrence of hepatocellular carcinoma after orthotopic liver transplantation. Transplant Proc 1995; 27: 1245-1246.
29. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403. (Pubitemid 32496976)
30. Shen BY, Li HW, Regimbeau JM, Belghiti J,. Recurrence after resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2002; 1: 401-405. (Pubitemid 36748774)
31. Han K, Tzimas GN, Barkun JS, Metrakos P, Tchervenkov JL, Hilzenrat N, et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol 2007; 21: 39-45. (Pubitemid 46277174)
32. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129-137.
33. Merani A, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, Toso C,. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011; doi:10.1016/j.jhep. 2010.12.040. [Epub ahead of print].
34. Yao FY, Kerlan RK Jr, Hirose R, Davern TJ III, Bass NM, Feng S, et al. Excellent outcomes following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48: 819-827.
35. Roberts JP, Venook A, Kerlan R, Yao F,. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transpl 2010; 16: 925-929.
36. Yamashiki N, Seki T, Wakabayashi M, Nakagawa T, Imamura M, Tamai T, et al. Usefulness of Lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein (AFP-L3) as a marker of distant metastasis from hepatocellular carcinoma. Oncol Rep 1999; 6: 1229-1232.
37. Kumada T, Nakano S, Takeda I, Kiriyama S, Sone Y, Hayashi K, et al. Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol 1999; 30: 125-130. (Pubitemid 29023661)
38. Oya H, Sato Y, Yamamoto S, Nakatsuka H, Kobayashi T, Hara Y, et al. Comparison between human-telomerase reverse transcriptase mRNA and alpha-fetoprotein mRNA as a predictive value for recurrence of hepatocellular carcinoma in living donor liver transplantation. Transplant Proc 2006; 38: 3636-3639. (Pubitemid 44908547)
39. Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23: 1541-1548.
40. Taketa K, Sekiya C, Namiki M, Akamatsu K, Ohta Y, Endo Y, Kosaka K,. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1990; 99: 508-518. (Pubitemid 20219108)
41. Aoyagi Y, Isemura M, Yosizawa Z, Suzuki Y, Sekine C, Ono T, Ichida F,. Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma. Biochim Biophys Acta 1985; 830: 217-223. (Pubitemid 15003673)
42. Carr BI, Kanke F, Wise M, Satomura S,. Clinical evaluation of Lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 2007; 52: 776-782.
43. Aoyagi Y, Oguro M, Yanagi M, Mita Y, Suda T, Suzuki Y, et al. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996; 77: 1781-1786. (Pubitemid 26125176)
44. Weitz IC, Liebman HA,. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993; 18: 990-997.
45. Walker NM, Stuart KA, Ryan RJ, Desai S, Saab S, Nicol JA, et al. Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology 2010; 51: 1683-1691.
46. Ijichi M, Takayama T, Matsumura M, Shiratori Y, Omata M, Makuuchi M,. Alpha-fetoprotein mRNA in the circulation as a predictor of postsurgical recurrence of hepatocellular carcinoma: a prospective study. Hepatology 2002; 35: 853-860. (Pubitemid 34258379)
47. Marubashi S, Dono K, Sugita Y, Asaoka T, Hama N, Gotoh K, et al. Alpha-fetoprotein mRNA detection in peripheral blood for prediction of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc 2006; 38: 3640-3642. (Pubitemid 44908452)
48. Cillo U, Vitale A, Navaglia F, Basso D, Montin U, Bassanello M, et al. Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. World J Gastroenterol 2005; 11: 6920-6925. (Pubitemid 43126047)
49. Yamashita T, Budhu A, Forgues M, Wang XW,. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007; 67: 10831-10839. (Pubitemid 350145912)
50. Sakamoto M, Mori T, Masugi Y, Effendi K, Rie I, Du W,. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma. Intervirology 2008; 51 (suppl 1): 42-45. (Pubitemid 351821841)
51. Roberts JP,. Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2005; 11 (suppl 2): S45-S46. (Pubitemid 43072614)
52. Sandroussi C, Guba M, Sandhu L, Dubay D, Ghanekar E, Selzner M, et al. Liver transplantation for HCC: characterization of recurrence and outcomes with aggressive multimodal treatment [abstract]. Am J Transplant 2010; 10 (suppl 4): 452.
53. Yamashiki N, Sugawara Y, Tamura S, Tateishi R, Yoshida H, Kaneko J, et al. Postoperative surveillance with monthly serum tumor markers after living-donor liver transplantation for hepatocellular carcinoma. Hepatol Res 2010; 40: 278-286.
54. Chan EY, Larson AM, Fix OK, Yeh MM, Levy AE, Bakthavatsalam R, et al. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl 2008; 14: 956-965. (Pubitemid 352003894)